Divi's Lab

₹3918.8 6.8 | 0.2%

WEBSITE BSE:532488 NSE : DIVI'S LAB. 18 May, 12:50

Market Cap ₹104030 Cr.

Stock P/E 75.1

P/B 8

Current Price ₹3918.8

Book Value ₹ 488

Face Value 2

52W High ₹4104

Dividend Yield 0.77%

52W Low ₹ 3050.2

Edit Ratio

Divi's Lab Research see more...

Overview Inc. Year: 1990Industry: Pharmaceuticals & Drugs

Divi's Laboratories Ltd manufactures Active Pharma Ingredients (APIs) and intermediates. The organization in a matter of short time multiplied their breadth of operations to offer whole turnkey solutions to the domestic Indian pharmaceutical enterprise.They are actively concerned in growing trade, patent non-infringing approaches for APIs, for the inventors to control late life cycle and leading customary drug producers.The company's product variety includes Bupropion Hbr,Bupropion HCL,Capecitabine,Carbidopa,Desloratadine,Dexlansoprazole /(R)-Lansoprazole, Irbesartan, Levodopa, Niacin, Sibutramine HCL, Valacyclovir HCL, Valsartan, Venlafaxine HCL, VerapamiL HCL, Vigabatrin, Zolpidem Tartrate ,and so forth.

Divi's Lab Share Price

New

Volume

Price

Price: NSE50 DMA200 DMAVolume

Quarterly Price

Quarterly Monthly

Show Value Show %

Peer Comparison

Divi's Lab Quarterly Results

#(Fig in Cr.)	Mar 2017	Jun 2017	Sep 2017	Dec 2017	Mar 2018
Net Sales	1067	821	890	1038	1088
Other Income	21	30	34	17	48
Total Income	1088	851	924	1055	1136
Total Expenditure	705	576	613	712	701
Operating Profit	383	275	311	343	435
Interest	1	0	1	0	-0
Depreciation	31	32	34	37	39
Exceptional Income / Expenses	0	0	0	0	0
Profit Before Tax	350	242	276	306	396
Provision for Tax	91	65	69	81	134
Profit After Tax	259	177	207	225	262
Adjustments	-259	-177	-207	-225	-262
Profit After Adjustments	0	0	0	0	0
Adjusted Earnings Per Share	9.8	6.7	7.8	8.5	9.9

Divi's Lab Profit & Loss

#(Fig in Cr.)	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	TTM
Net Sales	2129	2514	3084	3721	4024	3816	4880	5311	6799	8880	7625	3837
Other Income	49	84	43	96	76	112	157	190	63	114	349	129
Total Income	2177	2598	3127	3817	4100	3928	5036	5500	6862	8994	7974	3966
Total Expenditure	1306	1494	1921	2320	2585	2564	3030	3494	3978	5005	5276	2602
Operating Profit	871	1104	1206	1497	1515	1364	2007	2006	2884	3989	2698	1364
Interest	3	3	3	4	3	2	5	7	2	2	2	1
Depreciation	77	92	136	118	123	142	169	186	255	311	342	142
Exceptional Income / Expenses	0	0	0	0	0	0	0	0	0	0	0	0
Profit Before Tax	792	1009	1067	1375	1388	1219	1833	1813	2628	3677	2354	1220
Provision for Tax	180	217	220	264	335	350	501	441	673	728	546	349
Profit After Tax	611	792	847	1111	1053	870	1333	1373	1955	2949	1808	871
Adjustments	0	0	0	0	0	0	0	0	0	0	0	-871
Profit After Adjustments	611	792	847	1111	1053	870	1333	1373	1955	2949	1808	0
Adjusted Earnings Per Share	23	29.8	31.9	41.8	39.7	32.8	50.2	51.7	73.6	111.1	68.1	32.9

Growth Rates

#	1 Year	3 Year	5 Year	10 Year
Sales CAGR	-14%	13%	15%	14%
Operating Profit CAGR	-32%	10%	15%	12%
PAT CAGR	-39%	10%	16%	11%

#	1 Year	3 Year	5 Year	10 Year
Share Price CAGR	24%	-1%	19%	20%
ROE Average	15%	22%	21%	23%
ROCE Average	19%	29%	28%	30%

Divi's Lab Balance Sheet

#(Fig in Cr.)	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023
Shareholder's Funds	2553	3034	3562	4357	5409	5960	6973	7317	9272	11691	12705
Minority's Interest	0	0	0	0	0	0	0	0	0	0	0
Borrowings	2	2	1	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	475	655	847	92	1419	1770	994	294	363	448	568
Total Current Liabilities	552	623	772	516	656	640	833	1797	1705	2427	1510
Total Liabilities	3582	4314	5182	4965	7484	8370	8800	9408	11340	14567	14784
Fixed Assets	908	1222	1309	1439	1559	1996	2087	2776	3699	4321	4719
Other Non-Current Assets	800	813	1077	469	1886	1820	2065	1077	900	691	397
Total Current Assets	1874	2279	2796	3058	4039	4554	4647	5555	6741	9555	9667
Total Assets	3582	4314	5182	4965	7484	8370	8800	9408	11340	14567	14784

Divi's Lab Cash Flow

#(Fig in Cr.)	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023
Opening Cash & Cash Equivalents	8	6	10	9	-31	-17	-42	-8	28	2016	1200
Cash Flow from Operating Activities	483	558	822	1036	1149	765	964	1208	1947	1910	2448
Cash Flow from Investing Activities	-254	-305	-521	-411	-1137	-476	-684	-81	75	-2195	-2707
Cash Flow from Financing Activities	-231	-248	-303	-630	3	-314	-246	-1091	-34	-532	-797
Net Cash Inflow / Outflow	-2	5	-1	-5	15	-25	34	36	1988	-817	-1055
Closing Cash & Cash Equivalent	6	10	9	4	-17	-42	-8	28	2016	1200	144

Divi's Lab Ratios

#	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023
Earnings Per Share (Rs)	23.03	29.82	31.91	41.84	39.68	32.76	50.2	51.71	73.64	111.08	68.12
CEPS(Rs)	25.93	33.29	37.03	46.29	44.32	38.12	56.56	58.72	83.23	122.78	81
DPS(Rs)	15	20	20	10	10	10	16	16	20	30	30
Book NAV/Share(Rs)	96.18	114.3	134.18	164.13	203.76	224.51	262.7	275.63	349.28	440.44	478.64
Core EBITDA Margin(%)	38.36	40.27	37.39	37.37	35.39	32.62	37.6	33.83	41.36	43.42	30.6
EBIT Margin(%)	37.04	39.95	34.4	36.78	34.23	31.84	37.35	33.91	38.56	41.22	30.69
Pre Tax Margin(%)	36.92	39.83	34.3	36.68	34.14	31.78	37.26	33.77	38.53	41.2	30.66
PAT Margin (%)	28.51	31.27	27.23	29.62	25.91	22.66	27.08	25.57	28.66	33.04	23.55
Cash Profit Margin (%)	32.1	34.9	31.6	32.77	28.94	26.37	30.52	29.03	32.39	36.52	28.01
ROA(%)	19.15	20.05	17.84	21.89	16.92	10.97	15.52	15.08	18.84	22.76	12.32
ROE(%)	25.86	28.34	25.68	28.06	21.57	15.3	20.61	19.21	23.57	28.13	14.82
ROCE(%)	32.98	35.88	32.22	34.53	28.27	21.31	28.06	25.23	31.64	35.09	19.31
Receivable days	93.02	97.33	94.72	87.08	88.38	100.59	88.81	95.7	87.73	88.26	107.79
Inventory Days	124	122.46	117.81	110.86	108.57	120.67	109.22	115.82	101.33	95.85	128.95
Payable days	72.21	61.02	56.02	55.49	79.64	102.83	88.28	92.94	107.07	92.79	91.2
PER(x)	21.36	22.95	28.05	23.54	15.73	33.26	33.93	38.43	49.3	39.65	41.48
Price/Book(x)	5.11	5.99	6.67	6	3.06	4.85	6.48	7.21	10.39	10	5.9
Dividend Yield(%)	1.52	1.46	1.12	1.02	1.6	0.92	0.94	0.81	0.55	0.68	1.06
EV/Net Sales(x)	6.13	7.22	7.69	7.02	4.11	7.57	9.27	9.92	13.86	12.85	9.29
EV/Core EBITDA(x)	14.99	16.45	19.68	17.45	10.92	21.18	22.53	26.26	32.67	28.6	26.25
Net Sales Growth(%)	15.39	18.09	22.68	20.67	8.13	-5.17	27.88	8.83	28.02	30.61	-14.13
EBIT Growth(%)	13.54	27.38	5.78	28.9	0.89	-12.21	50.44	-0.95	44.46	39.87	-35.95
PAT Growth(%)	11.99	29.49	6.99	31.14	-5.18	-17.44	53.25	3.01	42.4	50.84	-38.68
EPS Growth(%)	11.99	29.49	6.99	31.14	-5.18	-17.44	53.25	3.01	42.4	50.84	-38.68
Debt/Equity(x)	0.01	0.01	0.01	0.01	0.01	0.01	0.02	0	0	0	0
Current Ratio(x)	3.4	3.66	3.62	5.93	6.16	7.11	5.58	3.09	3.95	3.94	6.4
Quick Ratio(x)	1.94	2.22	2.18	3.67	4.24	5.11	3.58	2.12	2.76	2.85	4.56
Interest Cover(x)	310.56	345.75	375.24	349.89	417.89	528.86	398.66	258.94	1452.86	2126.16	1393.96
Total Debt/Mcap(x)	0	0	0	0	0	0	0	0	0	0	0

Divi's Lab Shareholding Pattern

#	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024
Promoter	51.95	51.94	51.94	51.94	51.94	51.94	51.93	51.93	51.92	51.92
FII	19.3	18.45	16.52	15.4	15.14	14.67	14.7	14.6	14.86	14.68
DII	17.73	18.32	19.98	20.78	20.67	21.08	21.23	21.75	21.88	22.21
Public	11.02	11.28	11.56	11.88	12.24	12.31	12.14	11.73	11.34	11.19
Others	0	0	0	0	0	0	0	0	0	0
Total	100	100	100	100	100	100	100	100	100	100

#	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024
Promoter	13.79	13.79	13.79	13.79	13.79	13.79	13.79	13.79	13.78	13.78
FII	5.12	4.9	4.39	4.09	4.02	3.89	3.9	3.88	3.94	3.9
DII	4.71	4.86	5.3	5.52	5.49	5.59	5.64	5.77	5.81	5.9
Public	2.93	3	3.07	3.15	3.25	3.27	3.22	3.11	3.01	2.97
Others	0	0	0	0	0	0	0	0	0	0
Total	26.55	26.55	26.55	26.55	26.55	26.55	26.55	26.55	26.55	26.55

Pros

Company has a good return on equity (ROE) track record: 3 Years ROE 22%
Debtor days have improved from 92.79 to 91.2days.
Company is almost debt free.

Cons

Stock is trading at 8 times its book value.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Divi's Lab News

IPO

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Divi's Lab

Add Watchlist

Divi's Lab Research see more...

Overview Inc. Year: 1990Industry: Pharmaceuticals & Drugs

Divi's Lab Share Price

Alert Data

Quarterly Price

Peer Comparison

Divi's Lab Quarterly Results

Divi's Lab Profit & Loss

Growth Rates

Divi's Lab Balance Sheet

Divi's Lab Cash Flow

Divi's Lab Ratios

Divi's Lab Shareholding Pattern

Divi's Lab News

IPO

Stocx: India's #1 Marketplace to Find Your Winning Stock

Please Login!

Error!